Amarin Corp Plc (AMRN)

[dukesking]

I have to update my previous post. I went to stocktwits and found a link with the full SBV transcript. I was very encouraged by the following statement.
“Our objective is to maximize profitability and we can still do that even with Teva on the market unless there is significant erosion on the price. But, if there are unforeseen events, we have a plan for further operating expense reduction, obviously. But we are ready to enter into a branded generic mode, but also an authorized generic mode and other strategic ideas that would still allow us to be profitable in the U.S. and to generate the cash that is needed for us to invest in Europe and complete the launches across”.

Why this wasn’t addressed yesterday is beyond me. They left most of us with the impression that the US market is dead and being abandoned by AMRN. I personally believe this should be done before Teva launches fully or others generics enter the market and before generics have the API to saturate the market. Once AMRN loses more scripts to generics it will be much harder to get them back. IMO

https://seekingalpha.com/article/4578362-amarin-corporation-plc-amrn-svb-securities-global-biopharma-conference-transcript?utm_source=stck.pro&utm_medium=referral